Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution

Justin Tolman, Nicole A. Nelson, Yoen Ju Son, Stephanie Bosselmann, Nathan P. Wiederhold, Jay I. Peters, Jason T. McConville, Robert O. Williams

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Invasive fungal infections in immunocompromised patients have high mortality rates despite current treatment modalities. This study was designed to evaluate the suitability of an aqueous solution of voriconazole solubilized with sulfobutyl ether-β-cyclodextrin for targeted drug delivery to the lungs via nebulization. A solution was prepared such that the inspired aerosol dose was isotonic with an acceptable mass median aerodynamic diameter of 2.98 μm and a fine particle fraction of 71.7%. Following single and multiple inhaled doses, high voriconazole concentrations were observed within 30 min in the lung tissue and plasma. Drug solubilization with sulfobutyl ether-β-cyclodextrin contributed to the rapid and high drug concentrations in plasma following inhalation. Maximal concentrations in the lung and plasma were 11.0 ± 1.6 μg/g wet lung weight and 7.9 ± 0.68 μg/mL, respectively, following a single inhaled dose with a corresponding tissue/plasma concentration ratio of 1.4 to 1. Following multiple inhaled doses, peak concentrations in lung tissue and plasma were 6.73 ± 3.64 μg/g wet lung weight and 2.32 ± 1.52 μg/mL, respectively. AUC values in lung tissue and plasma were also high. The clinically relevant observed pharmacokinetic parameters of inhaled aqueous solutions of voriconazole suggest that therapeutic outcomes could be benefitted through the use of inhaled voriconazole.

Original languageEnglish
Pages (from-to)199-205
Number of pages7
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume72
Issue number1
DOIs
StatePublished - May 2009
Externally publishedYes

Fingerprint

Pharmacokinetics
Lung
Cyclodextrins
Pulmonary Edema
Ether
Pharmaceutical Preparations
Weights and Measures
Immunocompromised Host
Aerosols
Inhalation
Area Under Curve
Voriconazole
Mortality
Therapeutics

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Pharmaceutical Science

Cite this

Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution. / Tolman, Justin; Nelson, Nicole A.; Son, Yoen Ju; Bosselmann, Stephanie; Wiederhold, Nathan P.; Peters, Jay I.; McConville, Jason T.; Williams, Robert O.

In: European Journal of Pharmaceutics and Biopharmaceutics, Vol. 72, No. 1, 05.2009, p. 199-205.

Research output: Contribution to journalArticle

Tolman, J, Nelson, NA, Son, YJ, Bosselmann, S, Wiederhold, NP, Peters, JI, McConville, JT & Williams, RO 2009, 'Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution', European Journal of Pharmaceutics and Biopharmaceutics, vol. 72, no. 1, pp. 199-205. https://doi.org/10.1016/j.ejpb.2008.12.014
Tolman, Justin ; Nelson, Nicole A. ; Son, Yoen Ju ; Bosselmann, Stephanie ; Wiederhold, Nathan P. ; Peters, Jay I. ; McConville, Jason T. ; Williams, Robert O. / Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution. In: European Journal of Pharmaceutics and Biopharmaceutics. 2009 ; Vol. 72, No. 1. pp. 199-205.
@article{28362d7f84bf41b88ed1748c9e76bbab,
title = "Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution",
abstract = "Invasive fungal infections in immunocompromised patients have high mortality rates despite current treatment modalities. This study was designed to evaluate the suitability of an aqueous solution of voriconazole solubilized with sulfobutyl ether-β-cyclodextrin for targeted drug delivery to the lungs via nebulization. A solution was prepared such that the inspired aerosol dose was isotonic with an acceptable mass median aerodynamic diameter of 2.98 μm and a fine particle fraction of 71.7{\%}. Following single and multiple inhaled doses, high voriconazole concentrations were observed within 30 min in the lung tissue and plasma. Drug solubilization with sulfobutyl ether-β-cyclodextrin contributed to the rapid and high drug concentrations in plasma following inhalation. Maximal concentrations in the lung and plasma were 11.0 ± 1.6 μg/g wet lung weight and 7.9 ± 0.68 μg/mL, respectively, following a single inhaled dose with a corresponding tissue/plasma concentration ratio of 1.4 to 1. Following multiple inhaled doses, peak concentrations in lung tissue and plasma were 6.73 ± 3.64 μg/g wet lung weight and 2.32 ± 1.52 μg/mL, respectively. AUC values in lung tissue and plasma were also high. The clinically relevant observed pharmacokinetic parameters of inhaled aqueous solutions of voriconazole suggest that therapeutic outcomes could be benefitted through the use of inhaled voriconazole.",
author = "Justin Tolman and Nelson, {Nicole A.} and Son, {Yoen Ju} and Stephanie Bosselmann and Wiederhold, {Nathan P.} and Peters, {Jay I.} and McConville, {Jason T.} and Williams, {Robert O.}",
year = "2009",
month = "5",
doi = "10.1016/j.ejpb.2008.12.014",
language = "English",
volume = "72",
pages = "199--205",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution

AU - Tolman, Justin

AU - Nelson, Nicole A.

AU - Son, Yoen Ju

AU - Bosselmann, Stephanie

AU - Wiederhold, Nathan P.

AU - Peters, Jay I.

AU - McConville, Jason T.

AU - Williams, Robert O.

PY - 2009/5

Y1 - 2009/5

N2 - Invasive fungal infections in immunocompromised patients have high mortality rates despite current treatment modalities. This study was designed to evaluate the suitability of an aqueous solution of voriconazole solubilized with sulfobutyl ether-β-cyclodextrin for targeted drug delivery to the lungs via nebulization. A solution was prepared such that the inspired aerosol dose was isotonic with an acceptable mass median aerodynamic diameter of 2.98 μm and a fine particle fraction of 71.7%. Following single and multiple inhaled doses, high voriconazole concentrations were observed within 30 min in the lung tissue and plasma. Drug solubilization with sulfobutyl ether-β-cyclodextrin contributed to the rapid and high drug concentrations in plasma following inhalation. Maximal concentrations in the lung and plasma were 11.0 ± 1.6 μg/g wet lung weight and 7.9 ± 0.68 μg/mL, respectively, following a single inhaled dose with a corresponding tissue/plasma concentration ratio of 1.4 to 1. Following multiple inhaled doses, peak concentrations in lung tissue and plasma were 6.73 ± 3.64 μg/g wet lung weight and 2.32 ± 1.52 μg/mL, respectively. AUC values in lung tissue and plasma were also high. The clinically relevant observed pharmacokinetic parameters of inhaled aqueous solutions of voriconazole suggest that therapeutic outcomes could be benefitted through the use of inhaled voriconazole.

AB - Invasive fungal infections in immunocompromised patients have high mortality rates despite current treatment modalities. This study was designed to evaluate the suitability of an aqueous solution of voriconazole solubilized with sulfobutyl ether-β-cyclodextrin for targeted drug delivery to the lungs via nebulization. A solution was prepared such that the inspired aerosol dose was isotonic with an acceptable mass median aerodynamic diameter of 2.98 μm and a fine particle fraction of 71.7%. Following single and multiple inhaled doses, high voriconazole concentrations were observed within 30 min in the lung tissue and plasma. Drug solubilization with sulfobutyl ether-β-cyclodextrin contributed to the rapid and high drug concentrations in plasma following inhalation. Maximal concentrations in the lung and plasma were 11.0 ± 1.6 μg/g wet lung weight and 7.9 ± 0.68 μg/mL, respectively, following a single inhaled dose with a corresponding tissue/plasma concentration ratio of 1.4 to 1. Following multiple inhaled doses, peak concentrations in lung tissue and plasma were 6.73 ± 3.64 μg/g wet lung weight and 2.32 ± 1.52 μg/mL, respectively. AUC values in lung tissue and plasma were also high. The clinically relevant observed pharmacokinetic parameters of inhaled aqueous solutions of voriconazole suggest that therapeutic outcomes could be benefitted through the use of inhaled voriconazole.

UR - http://www.scopus.com/inward/record.url?scp=62949237100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62949237100&partnerID=8YFLogxK

U2 - 10.1016/j.ejpb.2008.12.014

DO - 10.1016/j.ejpb.2008.12.014

M3 - Article

VL - 72

SP - 199

EP - 205

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

IS - 1

ER -